As if finding bargain-priced stocks in a sky-high market werent difficult enough, investors who hunt for undervalued names face the threat of succumbing to value traps. These stocks masquerade as temporarily beaten-down shares of promising companies, but are, in fact, trading at depressed prices because of long-term problems with the business. The difference between true value plays and value traps becomes apparent in hindsight: The former eventually bounce back, while value traps continue to sag.
See Also: 7 Bargain Stocks in Today’s Pricey Market
Picking the winners is often more art than science. Start by asking yourself two questions, advises John Linehan, who manages a number of value-oriented mutual funds at T. Rowe Price. First, do the companys problems seem fixable within a time frame you can live with? If the answer is yes, the stock deserves further consideration. Second, imagine that the company didnt exist, then ask yourself if people would care. If the answer is no, says Linehan, youre probably looking at a company without staying power.
Top 10 Undervalued Stocks To Buy For 2019: Apricus Biosciences, Inc(APRI)
Advisors’ Opinion:
- [By Paul Ausick]
Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.
- [By Jon C. Ogg]
The biotechs and emerging pharma havebeen under pressure from politicians attacking drug prices. That doesn’t mean that there are not some big winners out there. Sometimes the biggest winners are companies most investors have never heard of. Even if you have been a biotech and emerging pharma investor for years, chances are high that you would have never heard of a small outfit called Apricus Biosciences Inc. (NASDAQ: APRI).
- [By Chris Lange]
Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDAs review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.
- [By William Romov]
California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).
Top 10 Undervalued Stocks To Buy For 2019: Internap Network Services Corporation(INAP)
Advisors’ Opinion:
- [By Lisa Levin]
Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 13 percent to $2.97 on strong quarterly results. Stifel Nicolaus upgraded Internap from Hold to Buy and raised the price target from $2.00 to $5.50.
- [By Alex McGuire]
These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…
Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%
As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.
- [By Lisa Levin]
Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 28 percent to $2.32 as the company reported that it has raised $43 million in a common equity private placement.
Top 10 Undervalued Stocks To Buy For 2019: Pacific Mercantile Bancorp(PMBC)
Advisors’ Opinion:
- [By Lisa Levin]
Shares of Pacific Mercantile Bancorp (NASDAQ: PMBC) were down 24 percent to $5.78. Pacific Mercantile Bancorp reported a Q3 loss of $30.5 million on revenue of $10.2 million for its third quarter.
Top 10 Undervalued Stocks To Buy For 2019: Vanguard FTSE Europe ETF (VGK)
Advisors’ Opinion:
- [By Todd Shriber, ETF Professor]
Perhaps the largest ETF dedicated to tracking French stocks should be getting more attention. In a year in which ETFs tracking the PIIGS economies are struggling, EWQ has been solid. The France ETF's 2.7 percent year-to-date gain is slightly ahead of the comparable Germany ETF and more than twice as good as the Vanguard FTSE Europe ETF (NYSE: VGK).
- [By Tom Aspray, Senior Editor, MoneyShow.com]
The US stock market is still leading with the Spyder Trust (SPY) up 18.6%, while the European markets (VGK) are now up close to 10% for the year, as they have gotten a nice boost in the past three weeks.
- [By Todd Shriber, ETF Professor]
Here is a dichotomy. Global small-caps are performing admirably. The WisdomTree Europe SmallCap Dividend Fund (NYSE: DFE) is an example of a Europe ETF that is defying some unfavorable trends. DFE is down 3.5 percent year-to-date. That sounds bad, but it is far better than what investors have been treated to with diversified, large-cap Europe ETFs. The Vanguard Europe ETF (NYSE: VGK) and the iShares Europe ETF (NYSE: IEV) are down an average of 5.3 percent this year.
- [By Todd Shriber, ETF Professor]
Still, there are instances of limited appetite for diversified Europe ETFs, particularly those with significant U.K. exposure. The Vanguard FTSE Europe ETF (NYSE: VGK) hasn't added (or lost) any capital since June 20. That ETF devotes 31.4 percent of its weight to U.K. stocks.
Top 10 Undervalued Stocks To Buy For 2019: Deltic Timber Corporation(DEL)
Advisors’ Opinion:
- [By Lisa Levin] Gainers
Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
Top 10 Undervalued Stocks To Buy For 2019: Qorvo, Inc.(QRVO)
Advisors’ Opinion:
- [By ]
TSMC fell 5.7% on Wednesday in response to the news. Apple, which relies on TSMC to manufacture its A-series system-on-chips (SoCs) and various other chips, fell 2.8%. iPhone/iPad chip suppliers such as Cirrus Logic (CRUS) , Broadcom (AVGO) , Skyworks (SWKS) and Qorvo (QRVO) , some of which also rely on TSMC, registered 3%-plus drops.
- [By Jim Robertson]
Yesterday, our Elite Opportunity Pronewsletter suggested picking up some mid cap radio frequency (RF) solutions stock Qorvo Inc (NASDAQ: QRVO) at current levels:
- [By WWW.THESTREET.COM]
Shares rose 6.3% after hours to $159.50, and made fresh highs. They’re now up 37% on the year. iPhone/iPad suppliers also got a boost: Cirrus Logic Inc. (CRUS) rose 4.2% to $65.70, Skyworks Solutions Inc. (SWKS) rose 3.1% to $107.50, Qorvo Inc. (QRVO) rose 2.7% to $69.90, Jabil Inc. (JBL) rose 1.2% to $30.78 and Broadcom Ltd. (AVGO) rose 2.8% to $255.40.
Top 10 Undervalued Stocks To Buy For 2019: CNO Financial Group, Inc.(CNO)
Advisors’ Opinion:
- [By ]
The Evercore analysts also said that Metlife Inc. (MET) and CNO Financial Group Inc. (CNO) have “sizable exposure” to long-term care from a reserve standpoint, “but our analysis indicates that their blocks have below average risk and/or more robust reserves versus peers, implying a lower risk of charges over the next few years.”
- [By Paul Ausick]
CNO Financial Group Inc. (NYSE: CNO) dropped about 8.1% on Friday to post a new 52-week low of $14.29 against a 52-week high of $20.88. Volume of more than 6 million was more than 3 times the daily average of around 1.8 million. The stock closed at $15.55 on Thursday night. The company on Thursday cut its re-insurance agreements with Beechwood Re following disclosure that regulators that many of Beechwood’s assets did not comply with insurance company guidelines.
Top 10 Undervalued Stocks To Buy For 2019: Biogen Idec Inc(BIIB)
Advisors’ Opinion:
- [By George Budwell]
Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.
- [By Chris Lange]
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.
- [By Brian Orelli]
While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.
Top 10 Undervalued Stocks To Buy For 2019: Crestwood Equity Partners LP(CEQP)
Advisors’ Opinion:
- [By Lisa Levin]
Crestwood Equity Partners LP (NYSE: CEQP) shares shot up 45 percent to $18.54 following the announcement of a new joint venture with Consolidated Edison, Inc. (NYSE: ED). Subsidiaries of both companies entered into an agreement on Thursday to form a joint venture in which they will jointly own and develop Crestwood’s existing natural gas pipeline and storage business in norther Pennsylvania and southern New York.
Top 10 Undervalued Stocks To Buy For 2019: RenaissanceRe Holdings Ltd.(RNR)
Advisors’ Opinion:
- [By Logan Wallace]
RenaissanceRe (NYSE: RNR) is one of 73 publicly-traded companies in the “Fire, marine, & casualty insurance” industry, but how does it compare to its rivals? We will compare RenaissanceRe to similar companies based on the strength of its dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.
- [By WWW.MONEYSHOW.COM]
RenaissanceRe Holdings (RNR) is a global provider of reinsurance, as well as various types of insurance and related services. The company was founded in 1993 and is headquartered in Bermuda, notes Jack Adamo, editor of Insiders Plus.
